Meiji Yasuda Life Insurance Co lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 41.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 4,715 shares of the medical instruments supplier’s stock after selling 3,385 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Becton Dickinson and were worth $1,177,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc grew its holdings in Becton Dickinson and by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock valued at $5,654,895,000 after buying an additional 283,433 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in Becton Dickinson and by 7.1% during the 4th quarter. Advisors Asset Management Inc. now owns 42,658 shares of the medical instruments supplier’s stock valued at $9,612,000 after buying an additional 2,840 shares in the last quarter. Gantzert Investment Co. LLC ADV purchased a new stake in Becton Dickinson and during the 4th quarter valued at approximately $2,209,000. Schmidt P J Investment Management Inc. grew its holdings in Becton Dickinson and by 15.5% during the 4th quarter. Schmidt P J Investment Management Inc. now owns 11,413 shares of the medical instruments supplier’s stock valued at $2,572,000 after buying an additional 1,535 shares in the last quarter. Finally, Hamilton Point Investment Advisors LLC grew its holdings in Becton Dickinson and by 3.5% during the 4th quarter. Hamilton Point Investment Advisors LLC now owns 32,063 shares of the medical instruments supplier’s stock valued at $7,224,000 after buying an additional 1,086 shares in the last quarter. Institutional investors own 84.58% of the company’s stock.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. UBS Group cut their target price on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, May 10th. Morgan Stanley cut their target price on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Finally, Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price for the company in a report on Monday, May 13th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $255.31.

In related news, EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares in the company, valued at $4,596,924.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the sale, the executive vice president now owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,664 shares of company stock valued at $6,924,334. 0.12% of the stock is owned by corporate insiders.

Shares of BDX stock traded down $0.02 on Wednesday, reaching $237.00. The company’s stock had a trading volume of 462,836 shares, compared to its average volume of 1,273,610. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. The firm has a market cap of $63.73 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 1.76 and a beta of 1.11.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same period last year, the firm posted $2.65 earnings per share. Becton Dickinson and’s revenue for the quarter was down .6% compared to the same quarter last year. On average, equities analysts predict that Becton Dickinson and Co will post 11.69 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a $0.77 dividend. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.30%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.

COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (NYSE:BDX) Shares Sold by Meiji Yasuda Life Insurance Co” was first published by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.mareainformativa.com/news/2019/06/12/becton-dickinson-and-co-nysebdx-shares-sold-by-meiji-yasuda-life-insurance-co.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Cryptocurrencies

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.